Dare Bioscience, Inc.
Dare Bioscience, Inc. (DARE): 8 pipeline candidates · 2 upcoming catalysts · ~11 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.7 months
D/E 36.89 · 0% dilution
Lead: Approved
8 candidates
2 upcoming, next in ~75d
N/A
A transparent, data-derived signal for Dare Bioscience, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$30.7M
Cash
$18.8M
Quarterly Burn
$5.5M
Runway
10.7 mo
Revenue
$152K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| dare to play sildenafil | Approved |
| dare to reclaim | Phase 1/Phase 2 |
| dare-hpv | Phase 2 |
| DARE-HRT1 | — |
| lopinavir / ritonavir | Phase 2 |
| Ovaprene | Phase 3 |
| Sildenafil Cream, 3.6% | Phase 2 |
| XACIATO | Approved |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$2.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 924,610 | $1.7M |
| geode capital management, llc | 177,839 | $324K |
| vanguard fiduciary trust co | 65,938 | $120K |
| state street corp | 23,515 | $43K |
| xtx topco ltd | 22,339 | $41K |
| susquehanna international group, llp | 17,130 | $31K |
| blackrock, inc. | 16,971 | $31K |
| northern trust corp | 15,431 | $28K |
| raymond james financial inc | 15,334 | $28K |
| lpl financial llc | 14,639 | $27K |
Showing top 10 of 24 institutional holders of Dare Bioscience, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Dare Bioscience, Inc.'s pipeline?
Dare Bioscience, Inc. (DARE) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dare Bioscience, Inc.'s lead drug candidate?
Dare Bioscience, Inc.'s most advanced tracked candidate is dare to play sildenafil (Approved) for female sexual arousal disorder.
What is Dare Bioscience, Inc.'s next catalyst?
Dare Bioscience, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone " — expected September 1, 2026.
What is Dare Bioscience, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dare Bioscience, Inc. has approximately 10.7 months of cash runway.
What is Dare Bioscience, Inc.'s market capitalization?
Dare Bioscience, Inc.'s market capitalization is approximately $30.7M.
Get the full picture on Dare Bioscience, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.